Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

Meth use accounts for nearly 1 in 6 heart attacks, California study shows

Methamphetamine (meth) use accounted for nearly 15% of heart attacks for a decade in a northern California study, published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

30 Apr 2026

New screening tool predicts health risks for people living with obesity

A simple tool, developed by researchers at Queen Mary University of London and the Berlin Institute of Health at Charité, could help identify which people living with obesity or overweight are most likely to develop serious obesity-related conditions such as type 2 diabetes and heart disease.

30 Apr 2026

Brief walking breaks help the body control sugar after carb-rich meals

Brief brisk walking breaks during prolonged sitting improved post-meal interstitial glucose responses in healthy adults after carbohydrate-rich meals, with the strongest effects seen in women. Gluteal fat showed a more stable glucose pattern than abdominal fat, suggesting it may help buffer carbohydrate-related glucose rises through depot-specific uptake and lipid-synthesis pathways.

29 Apr 2026

New genetic risk test estimates inherited risk for cardiovascular conditions

Researchers at Mass General Brigham Heart and Vascular Institute and collaborators have developed and validated a new genetic risk test that can estimate a person's inherited risk for eight common cardiovascular conditions, offering a more comprehensive approach to prevention.

29 Apr 2026

New hybrid molecule uses Trojan horse approach to treat obesity

A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signalling pathway as a "door opener" and delivers an additional metabolic modulator specifically into the target cells.

29 Apr 2026

AI eye screening shows promise for detecting six metabolic diseases

Researchers developed Reti-Pioneer, an AI retinal imaging framework that screened for six endocrine and metabolic diseases using color fundus photographs and clinical metadata. The system showed moderate-to-strong performance across cohorts, improved specialist decision-making, and demonstrated promising, though still preliminary, potential for faster, scalable disease screening.

29 Apr 2026

Electroacupuncture promotes weight loss by turning white fat into brown

Globally rising obesity rates pose major health risks, including type 2 diabetes, cardiovascular disease, and certain malignancies.

28 Apr 2026

New scientific statement defines brain health across life

Brain health isn't determined only by genetics or what happens later in life. A growing body of research shows that a range of factors-from mental health and sleep to environment, lifestyle and social conditions-play a powerful role in shaping how the brain functions and ages.

28 Apr 2026

Lipid pathways driving diabetes and heart disease risk in South Asians

Identifying lipid-linked genetic pathways in Asian Indians offers insights into diabetes and heart disease, crucial for developing ancestry-specific therapies.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

GLP-1 weight loss is driven mainly by fat loss, not muscle loss

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest. The findings suggest these treatments can support higher-quality weight loss when paired with individualized care, nutrition, and resistance training.

27 Apr 2026

Obesity leaves lasting molecular tags on the immune system

People who live with obesity are 'tagging' a memory of being overweight on a key part of the immune system - leaving people with ongoing risk of obesity-related conditions years after losing weight, according to a 10 year-long study published in EMBO Reports.

27 Apr 2026

Study identifies epigenetic patterns affecting insulin and glucagon production in type 2 diabetes

Researchers at Lund University in Sweden have carried out the most detailed mapping to date of the epigenome in the cells that regulate the body's blood sugar levels.

24 Apr 2026

Drinking coffee alters your microbiome, mood, and memory

Coffee consumption influences the microbiota-gut-brain axis, affecting cognitive performance and emotional regulation through complex biological pathways.

24 Apr 2026

Study identifies new genetic pathways driving cardiometabolic disease risk

A study published today in PLOS Medicine has identified two new genetic pathways that contribute to cardiometabolic disease, which includes heart disease, obesity and diabetes.

23 Apr 2026

Real-time CGM transforms blood glucose management in type 2 diabetes

A major clinical trial has found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults living with type 2 diabetes who are treated with basal insulin.

23 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

APOLLO AI learns from 25 billion medical events to predict future disease

APOLLO is a multimodal temporal foundation model trained on 25.2 billion medical events from 7.2 million patients across 33 years of Mass General Brigham records, integrating 28 medical modalities into unified “virtual patient representations.” Across 322 downstream tasks, the model showed strong performance in disease prediction, treatment-response stratification, hospital operations, and patient retrieval, supporting the idea of more computable, data-driven medicine.

23 Apr 2026